secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ocugen, Inc. (OCGN)
CIK:        0001372299
Form:       8-K
Filed at:   2023-05-05T23:59:59+00:00
Accession:  0001628280-23-015993
Event type: regulatory
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 3.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocugen receives Nasdaq bid price deficiency notice and reports Q1 net loss of $0.07 per share
--------------------------------------------------------------------------------

- Nasdaq notified Ocugen on May 1 that its stock closed below $1.00 for 30 consecutive days; 180-day cure period until Oct 30, 2023.
- Cash and investments $76.7M at March 31, 2023, down from $90.9M at Dec 31, 2022; funding expected into Q1 2024.
- Net loss per share $0.07 in Q1 2023 vs $0.09 in Q1 2022; total operating expenses $17.8M.
- OCU400 Phase 1/2 shows positive preliminary efficacy/safety; FDA approved pediatric enrollment; Phase 3 trial planned late 2023.
- COVAXIN development in North America discontinued; shift to inhaled mucosal vaccine platform (flu and COVID-19).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372299/000162828023015993/0001628280-23-015993-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372299/000162828023015993/ocgn-20230501.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-015993

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer